TRP频道:乳腺癌化学疗法耐药性的被忽视的罪祸首?
Mayar Soussi1, Alice Hasselsweiller1, Dimitra Gkika1
1Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
暂时受体潜力 (TRP) 道对于乳腺癌的发展和治疗耐药性至关重要. 针对这些道提供了一个有希望的策略,以改善乳腺癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是全球领先的健康问题.
- 耐疗性显著复杂化了乳腺癌的治疗.
- 暂时受体潜力 (TRP) 通道与癌症特征有关.
研究的目的:
- 研究TRP通道在乳腺癌治疗耐药性的作用.
- 探索向TRP通道的潜力,以克服治疗耐药性.
主要方法:
- 对乳腺癌中TRP通道的现有文献的审查.
- 对TRP通道功能在调节药物反应中的分析.
- 探索针对TRP道的治疗策略.
主要成果:
- 在致癌的多个方面,TRP通道是关键参与者.
- TRP通道调节细胞对各种药物剂的反应.
- 有证据表明,TRP通道有助于乳腺癌的治疗抵抗.
结论:
- TRP通道正在成为乳腺癌治疗耐药性的关键媒介.
- 准TRP通道是一个有前途的治疗途径,可以提高治疗效率.
- 对TRP通道调节的进一步研究可能会导致新的乳腺癌疗法.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:19Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
